个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共32条记录   Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review [作者：Liao, XY; Morikawa, T; Lochhead, P; Imamura, Y; Kuchiba, A; Yamauchi, M; Nosho, K; Qian, ZR; Nishihara, R; Meyerhardt, JA; Fuchs, CS; Ogino, S,期刊：Clinical Cancer Research, 页码：2257-2268 , 文章类型： Review，,卷期：2012年18-8] Purpose: Mutations in PIK3CA [the gene encoding the p110a catalytic subunit of phosphatidylinositide-3-kinase (PI3K)] play an important role in colorectal carcinogenesis. Experimental evidence suggests that PIK3CA exon 9... cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes [作者：Raghav, KP; Wang, WT; Liu, SY; Chavez-MacGregor, M; Meng, XL; Hortobagyi, GN; Mills, GB; Meric-Bernstam, F; Blumenschein, GR; Gonzalez-Angulo, AM,期刊：Clinical Cancer Research, 页码：2269-2277 , 文章类型： Article，,卷期：2012年18-8] Purpose: To evaluate cMET (mesenchymal-epithelial transition factor gene) and phospho-cMET (p-cMET) levels in breast cancer subtypes and its impact on survival outcomes. Experimental Design: We measured protein levels of... Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma [作者：Wheeler, S; Siwak, DR; Chai, R; LaValle, C; Seethala, RR; Wang, L; Cieply, K; Sherer, C; Joy, C; Mills, GB; Argiris, A; Siegfried, JM; Grandis, JR; Egloff, AM,期刊：Clinical Cancer Research, 页码：2278-2289 , 文章类型： Article，,卷期：2012年18-8] Purpose: To assess the prognostic value of epidermal growth factor receptor (EGFR) molecular characteristics of head and neck squamous cell carcinoma (HNSCC). Patients and Methods: HNSCC tumors from patients prospectivel... Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma [作者：Llovet, JM; Pena, CEA; Lathia, CD; Shan, M; Meinhardt, G; Bruix, J,期刊：Clinical Cancer Research, 页码：2290-2300 , 文章类型： Article，,卷期：2012年18-8] Purpose: Validated biomarkers of prognosis and response to drug have not been identified for patients with hepatocellular carcinoma (HCC). One of the objectives of the phase III, randomized, controlled Sorafenib HCC Asse... The Use and Interpretation of Competing Risks Regression Models [作者：Dignam, JJ; Zhang, Q; Kocherginsky, M,期刊：Clinical Cancer Research, 页码：2301-2308 , 文章类型： Article，,卷期：2012年18-8] Purpose: Competing risks observations, in which patients are subject to a number of potential failure events, are a feature of most clinical cancer studies. With competing risks, several modeling approaches are available... Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints [作者：Sharma, MR; Karrison, TG; Jin, YY; Bies, RR; Maitland, ML; Stadler, WM; Ratain, MJ,期刊：Clinical Cancer Research, 页码：2309-2315 , 文章类型： Article，,卷期：2012年18-8] Purpose: The best phase II design and endpoint for growth inhibitory agents is controversial. We simulated phase II trials by resampling patients from a positive (sorafenib vs. placebo; TARGET) and a negative (AE941 vs. ... The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer [作者：Shimizu, T; Tolcher, AW; Papadopoulos, KP; Beeram, M; Rasco, DW; Smith, LS; Gunn, S; Smetzer, L; Mays, TA; Kaiser, B; Wick, MJ; Alvarez, C; Cavazos, A; Mangold, GL; Patnaik, A,期刊：Clinical Cancer Research, 页码：2316-2325 , 文章类型： Article，,卷期：2012年18-8] Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We investigated safety, efficacy, and correlations between tumor ... BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency [作者：Hong, DS; Vence, L; Falchook, G; Radvanyi, LG; Liu, CW; Goodman, V; Legos, JJ; Blackman, S; Scarmadio, A; Kurzrock, R; Lizee, G; Hwu, P,期刊：Clinical Cancer Research, 页码：2326-2335 , 文章类型： Article，,卷期：2012年18-8] Purpose: An intact immune system likely contributes to the outcome of treatment and may be important for clearance of drug-resistant tumor cells and for prevention of recurrence. Although pharmacologic inhibition of BRAF... A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck [作者：De Souza, JA; Davis, DW; Zhang, YJ; Khattri, A; Seiwert, TY; Aktolga, S; Wong, SJ; Kozloff, MF; Nattam, S; Lingen, MW; Kunnavakkam, R; Stenson, KM; Blair, EA; Bozeman, J; Dancey, JE; Vokes, EE; Cohen, EEW,期刊：Clinical Cancer Research, 页码：2336-2343 , 文章类型： Article，,卷期：2012年18-8] Purpose: This study sought to determine the efficacy and safety profile of lapatinib in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Experimental Design: This phase II multiins... A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors [作者：Rajan, A; Carter, CA; Kelly, RJ; Gutierrez, M; Kummar, S; Szabo, E; Yancey, MA; Ji, JP; Mannargudi, B; Woo, S; Spencer, S; Figg, WD; Giaccone, G,期刊：Clinical Cancer Research, 页码：2344-2351 , 文章类型： Article，,卷期：2012年18-8] Purpose: To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination. E... Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study [作者：Shamash, J; Jacob, J; Agrawal, S; Powles, T; Mutsvangwa, K; Wilson, P; Stebbing, J,期刊：Clinical Cancer Research, 页码：2352-2359 , 文章类型： Article，,卷期：2012年18-8] Purpose: Nontaxane-based chemotherapeutic options in castrate-resistant prostate cancer (CRPC) are limited despite the long natural history of the disease. We carried out a phase 1 dose-escalation study of the alkylating... DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-Small Cell Lung Cancer [作者：Walter, K; Holcomb, T; Januario, T; Du, P; Evangelista, M; Kartha, N; Iniguez, L; Soriano, R; Huw, L; Stern, H; Modrusan, Z; Seshagiri, S; Hampton, GM; Amler, LC; Bourgon, R; Yauch, RL; Shames, DS,期刊：Clinical Cancer Research, 页码：2360-2373 , 文章类型： Article，,卷期：2012年18-8] Purpose: Non-small cell lung cancers (NSCLC) comprise multiple distinct biologic groups with different prognoses. For example, patients with epithelial-like tumors have a better prognosis and exhibit greater sensitivity ... Analyzing the Pivotal Trial That Compared Sunitinib and IFN-alpha in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth [作者：Stein, WD; Wilkerson, J; Kim, ST; Huang, X; Motzer, RJ; Fojo, AT; Bates, SE,期刊：Clinical Cancer Research, 页码：2374-2381 , 文章类型： Article，,卷期：2012年18-8] Purpose: We applied a method that analyzes tumor response, quantifying the rates of tumor growth (g) and regression (d), using tumor measurements obtained while patients receive therapy. We used data from the phase III t... Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment [作者：Finegold, DN; Baty, CJ; Knickelbein, KZ; Perschke, S; Noon, SE; Campbell, D; Karlsson, JM; Huang, D; Kimak, MA; Lawrence, EC; Feingold, E; Meriney, SD; Brufsky, AM; Ferrell, RE,期刊：Clinical Cancer Research, 页码：2382-2390 , 文章类型： Article，,卷期：2012年18-8] Purpose: Secondary lymphedema is a frequent complication of breast cancer associated with surgery, chemotherapy, or radiation following breast cancer treatment. The potential contribution of genetic susceptibility to ris... Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib [作者：Punnoose, EA; Atwal, S; Liu, WQ; Raja, R; Fine, BM; Hughes, BGM; Hicks, RJ; Hampton, GM; Amler, LC; Pirzkall, A; Lackner, MR,期刊：Clinical Cancer Research, 页码：2391-2401 , 文章类型： Article，,卷期：2012年18-8] Purpose: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or their use for predictive biomarker eva... Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial [作者：Cheang, MCU; Voduc, KD; Tu, DS; Jiang, S; Leung, S; Chia, SK; Shepherd, LE; Levine, MN; Pritchard, KI; Davies, S; Stijleman, IJ; Davis, C; Ebbert, MTW; Parker, JS; Ellis, MJ; Bernard, PS; Perou, CM; Nielsen, TO,期刊：Clinical Cancer Research, 页码：2402-2412 , 文章类型： Article，,卷期：2012年18-8] Purpose: Recent studies suggest that intrinsic breast cancer subtypes may differ in their responsiveness to specific chemotherapy regimens. We examined this hypothesis on NCIC.CTG MA. 5, a clinical trial randomizing prem...